Natus Medical (BABY) to Release Quarterly Earnings on Thursday

Natus Medical (NASDAQ:BABY) will be announcing its earnings results after the market closes on Thursday, July 25th. Analysts expect the company to announce earnings of $0.30 per share for the quarter. Natus Medical has set its Q2 guidance at $0.25-0.32 EPS and its FY19 guidance at $1.17-1.44 EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.

Natus Medical (NASDAQ:BABY) last released its earnings results on Thursday, April 25th. The medical equipment provider reported $0.09 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.03. Natus Medical had a negative net margin of 8.62% and a positive return on equity of 10.75%. The business had revenue of $114.80 million for the quarter, compared to analyst estimates of $113.30 million. During the same period last year, the company posted $0.24 EPS. The business’s revenue was down 10.7% on a year-over-year basis. On average, analysts expect Natus Medical to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

BABY opened at $27.16 on Wednesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.70 and a quick ratio of 1.18. The business has a 50 day simple moving average of $25.30. Natus Medical has a 1-year low of $23.53 and a 1-year high of $37.90. The stock has a market cap of $923.60 million, a price-to-earnings ratio of 19.13 and a beta of 0.57.



A number of research firms have weighed in on BABY. BidaskClub lowered shares of YY from a “sell” rating to a “strong sell” rating in a research note on Tuesday. TheStreet lowered shares of Trinity Industries from a “b” rating to a “c” rating in a research report on Thursday, April 25th. Zacks Investment Research lowered shares of Hancock Jaffe Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, June 26th. Finally, ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $36.00.

In other news, Director Robert A. Gunst sold 8,000 shares of Natus Medical stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $26.73, for a total transaction of $213,840.00. Following the sale, the director now owns 26,392 shares of the company’s stock, valued at approximately $705,458.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Austin Francis Noll III sold 14,250 shares of Natus Medical stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $26.43, for a total transaction of $376,627.50. Following the sale, the vice president now directly owns 99,443 shares in the company, valued at approximately $2,628,278.49. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 48,515 shares of company stock worth $1,264,239. Corporate insiders own 1.65% of the company’s stock.

Natus Medical Company Profile

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Read More: Moving Average – How it Helps Investors in Stock Selection

Earnings History for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.